Pharmafile Logo

Pharmaceutical Development Services Ltd

Pharmaceutical Development Services Limited (PDS) is a pharmaceutical and regulatory consultancy serving the pharmaceutical, biopharmaceutical, medical device and cosmetic industries. The role of PDS is to tell you the current standards for your development regulatory submissions, and what you need to do to meet them. We explain why you need to do what needs to be done, and help you to generate data which will successfully meet the requirements.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Company Details

Biocity Nottingham, Pennyfoot St, Nottingham, NG1 1GF, United Kingdom
+44 (0)115 912 4277

 Latest Content from PMHub 

Lucid Group kick off their Winter Festival

The start of December not only signalled the official calendar countdown to Christmas, but also marked the official launch of the Lucid Winter Festival, which culminates in the Winter Summit...

What does the Five Year Forward View mean for pharma?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.

Healthcare in the Digital Age

White Papers and Resources | December 3, 2016 | M3 (EU)

Healthcare is changing. By understanding the needs of the physicians, and using innovative channels to make meaningful connections, pharma can ensure it continues to enjoy a mutually beneficial relationship.

M3 announces further expansion into Europe and Latin America with the acquisition of Vidal Group

Press Releases | December 3, 2016 | M3 (EU)

M3 is strengthening and growing its global operations with the acquisition of Vidal Group, a trusted provider of prescribing information and clinical decision support services to doctors and other HCPs...

Telehealth Research

White Papers and Resources | December 1, 2016 | Inizio

The remote exchange of data between patients and their clinician

Leading Edge expands their senior medical writing team

Leading Edge, part of the Lucid Group specialising in strategic health communications and medical education, has bolstered its senior medical writing team with the new appointment of Jennifer (Jennie) Badger. Jennie...

Web Summit Lisbon: Technology trends that will impact pharma

Digital technology is transforming every aspect of life. Here’s the most important trends pharma companies should watch, as observed by Anthill at Websummit earlier this month:

Living with Crohn’s disease: a patient perspective

Account Executive Victoria Morton explores what it’s like to live with Crohn’s disease as a young person, and investigates what’s being done to tackle the gaps in treatment options for...

Lucid win PMEA Support Agency of the Year 2016

Last night the Lancaster London Hotel hosted the annual PMEA awards. These awards recognise and commend companies and programmes demonstrating excellence, best practice and innovation in improving patient outcomes on...

Case Study: Understanding the patient journey and addiction treatment pathways

White Papers and Resources | November 23, 2016 | Inizio

Our client had previously conducted some research and knew that a large proportion of target patients also had addiction issues. They wanted to know more about addiction treatment pathways and...